



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 11 November 2019

Re: Freedom of Information Request
Ref: 248 - 2019

Thank you for your email dated the 6th September 2019, requesting information regarding cancer treatments.

The information that you require is as follows:

Please note, in accordance with the Data Protection Act 2018 our Trust is unable to release all of the information requested. The Clatterbridge Cancer Centre NHS Foundation Trust (CCC) is a relatively small Trust and by providing this level of detail where the number of patients is less than or equal to five increases any 'potential' risk of this data becoming identifiable information and thereby contravening one or more of the Data Protection Principles by releasing it into the public domain. Confidentiality is expected in such matters. This information is therefore exempt under Section 40: Personal Information, of the Freedom of Information Act 2000. The areas where this exemption has been applied are shown below:

Question 1a

Does your trust treat advanced breast cancer?

Yes

Question 1b

If none, where are your patients referred?

N/A

Question 2

In the past 3 months, how many advanced breast cancer patients [Stage IV] have the status of;

Points of note:

- The Clatterbridge Cancer Centre (CCC) only records TNM staging at presentation, therefore, the figures below are only illustrative of patients in the last three months who were diagnosed 1st June – 31st August 2019 and who were stage 4 at presentation to CCC.
- We record ER and PR status rather than a general HR status. We have included all of this information in a new table below the one that was provided as part of your request

HR+ and HER2+ [Hormone receptor-positive and human epidermal growth factor 2-positive]	
HR+ and HER2- [Hormone receptor-positive and human epidermal growth factor 2-negative]	
HR- and HER2+ [Hormone receptor-negative and human epidermal growth factor 2-positive]	
HR- and HER2- [Hormone receptor-negative and human epidermal growth factor 2-negative] - Triple negative disease	
Not Known	

Our response:

PR	ER	HER2			Total
		NEGATIVE	POSITIVE	NOT KNOWN	
POSITIVE	POSITIVE	8	Exempt under S.40	0	
NEGATIVE	NEGATIVE	Exempt under S.40	Exempt under S.40	Exempt under S.40	
	POSITIVE	Exempt under S.40	0	0	
NOT KNOWN	POSITIVE	Exempt under S.40	0	0	
Total		15	Exempt under S.40	Exempt under S.40	21

Question 3

Point of note:

- **1st June – 31st August 2019 – some patients had more than one regime in the period.**
- **We do not record aromatase inhibitors (Anastrozole, Exemestane and Letrozole) provided with SACT if this has been commenced and carried on by GP's.**

In the past 3 months, how many breast cancer patients were treated with:

Abemaciclib (Verzenios) + aromatase inhibitor * = 0

Abemaciclib (Verzenios) + Fulvestrant (Faslodex) = 18

Alpelisib (Piqray) + Fulvestrant (Faslodex) = 0

Atezolizumab (Tecentriq) = 0**

Bevacizumab (Avastin) = 0

Eribulin (Halaven) = 17

Everolimus (Afinitor) + Exemestane = 10

Fulvestrant (Faslodex) as a single agent = 22

Gemcitabine + paclitaxel = Exempt under S.40

Lapatinib (Tyverb) = 0

Neratinib (Nerlynx) = 0

Olaparib (Lynparza) = 0

Palbociclib (Ibrance) + aromatase inhibitor* = 171

Pertuzumab (Perjeta) + trastuzumab + docetaxel = 38

Ribociclib (Kisqali) + aromatase inhibitor* = Exempt under S.40

Ribociclib (Kisqali) + Fulvestrant (Faslodex) = 0

Talazoparib (Talzenna) = 0

Trastuzumab + paclitaxel = 12

Trastuzumab as a single agent = 204

Trastuzumab emtansine (Kadcyla) = 27

Other active systemic anti-cancer therapy ** = 673

***aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole**

****e.g. docetaxel, vinorelbine or capecitabine as a single agent**

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>